secwatch / observer
8-K filed April 27, 2026, 7:59 PM ET ticker INM CIK 0001728328
other material confidence high sentiment negative materiality 0.75

InMed reduces exercise price of Sabby and Wainwright preferred investment options to $0.80

InMed Pharmaceuticals Inc.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

InMed Pharmaceuticals Inc. issued up to 153,236 common shares (on a post-consolidation basis) of warrant to affiliates of H.C. Wainwright & Co., LLC for amended the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.

Security
warrant
Shares
up to 153,236 common shares (on a post-consolidation basis)
Purchaser
affiliates of H.C. Wainwright & Co., LLC
Consideration
amended the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80
Exact text from the filing
On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

InMed Pharmaceuticals Inc. issued up to 2,151,478 common shares of warrant to Sabby Volatility Warrant Master Fund, Ltd. for amended the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.

Security
warrant
Shares
up to 2,151,478 common shares
Purchaser
Sabby Volatility Warrant Master Fund, Ltd.
Consideration
amended the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80
Exact text from the filing
On April 21, 2026, the Company entered into a Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

InMed Pharmaceuticals Inc. amended Sabby Preferred Investment Option Amending Agreement with Sabby Volatility Warrant Master Fund, Ltd. (effective 2026-04-21).

Action
amendment
Agreement
equity purchase
Counterparty
Sabby Volatility Warrant Master Fund, Ltd.
Effective
2026-04-21
Exact text from the filing
On April 21, 2026, the Company entered into a Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

InMed Pharmaceuticals Inc. amended Wainwright Preferred Investment Option Amending Agreements with affiliates of H.C. Wainwright & Co., LLC (effective 2026-04-24).

Action
amendment
Agreement
equity purchase
Counterparty
affiliates of H.C. Wainwright & Co., LLC
Effective
2026-04-24
Exact text from the filing
On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.
View on SEC.gov

Browse all equity issuances →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR
accession 0001213900-26-048064
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.